These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1041 related articles for article (PubMed ID: 33566361)

  • 1. Benefits and potential harms of human papillomavirus (HPV)-based cervical cancer screening: A real-world comparison of HPV testing versus cytology.
    Thomsen LT; Kjaer SK; Munk C; Ørnskov D; Waldstrøm M
    Acta Obstet Gynecol Scand; 2021 Mar; 100(3):394-402. PubMed ID: 33566361
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical performance of human papillomavirus based cervical cancer screening algorithm: The result of a large Danish implementation study.
    Lindquist S; Kjær SK; Frederiksen K; Ørnskov D; Petersen LK; Munk C; Waldstrøm M
    Acta Obstet Gynecol Scand; 2024 Sep; 103(9):1781-1788. PubMed ID: 39012789
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Performance of carcinogenic human papillomavirus (HPV) testing and HPV16 or HPV18 genotyping for cervical cancer screening of women aged 25 years and older: a subanalysis of the ATHENA study.
    Castle PE; Stoler MH; Wright TC; Sharma A; Wright TL; Behrens CM
    Lancet Oncol; 2011 Sep; 12(9):880-90. PubMed ID: 21865084
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Age-specific evaluation of primary human papillomavirus screening vs conventional cytology in a randomized setting.
    Leinonen M; Nieminen P; Kotaniemi-Talonen L; Malila N; Tarkkanen J; Laurila P; Anttila A
    J Natl Cancer Inst; 2009 Dec; 101(23):1612-23. PubMed ID: 19903804
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Human papillomavirus testing and liquid-based cytology: results at recruitment from the new technologies for cervical cancer randomized controlled trial.
    Ronco G; Segnan N; Giorgi-Rossi P; Zappa M; Casadei GP; Carozzi F; Dalla Palma P; Del Mistro A; Folicaldi S; Gillio-Tos A; Nardo G; Naldoni C; Schincaglia P; Zorzi M; Confortini M; Cuzick J;
    J Natl Cancer Inst; 2006 Jun; 98(11):765-74. PubMed ID: 16757701
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cervical screening with primary HPV testing or cytology in a population of women in which those aged 33 years or younger had previously been offered HPV vaccination: Results of the Compass pilot randomised trial.
    Canfell K; Caruana M; Gebski V; Darlington-Brown J; Heley S; Brotherton J; Gertig D; Jennett CJ; Farnsworth A; Tan J; Wrede CD; Castle PE; Saville M
    PLoS Med; 2017 Sep; 14(9):e1002388. PubMed ID: 28926579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Health technology assessment report: HPV DNA based primary screening for cervical cancer precursors].
    Ronco G; Biggeri A; Confortini M; Naldoni C; Segnan N; Sideri M; Zappa M; Zorzi M; Calvia M; Accetta G; Giordano L; Cogo C; Carozzi F; Gillio Tos A; Arbyn M; Mejier CJ; Snijders PJ; Cuzick J; Giorgi Rossi P
    Epidemiol Prev; 2012; 36(3-4 Suppl 1):e1-72. PubMed ID: 22828243
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Results at recruitment from a randomized controlled trial comparing human papillomavirus testing alone with conventional cytology as the primary cervical cancer screening test.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Gillio-Tos A; Minucci D; Naldoni C; Rizzolo R; Schincaglia P; Volante R; Zappa M; Zorzi M; Cuzick J; Segnan N;
    J Natl Cancer Inst; 2008 Apr; 100(7):492-501. PubMed ID: 18364502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The clinical effectiveness and cost-effectiveness of primary human papillomavirus cervical screening in England: extended follow-up of the ARTISTIC randomised trial cohort through three screening rounds.
    C Kitchener H; Canfell K; Gilham C; Sargent A; Roberts C; Desai M; Peto J
    Health Technol Assess; 2014 Apr; 18(23):1-196. PubMed ID: 24762804
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Optimal Management Strategies for Primary HPV Testing for Cervical Screening: Cost-Effectiveness Evaluation for the National Cervical Screening Program in Australia.
    Simms KT; Hall M; Smith MA; Lew JB; Hughes S; Yuill S; Hammond I; Saville M; Canfell K
    PLoS One; 2017; 12(1):e0163509. PubMed ID: 28095411
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of HPV DNA testing with cytology triage and/or repeat HPV DNA testing in primary cervical cancer screening.
    Naucler P; Ryd W; Törnberg S; Strand A; Wadell G; Elfgren K; Rådberg T; Strander B; Forslund O; Hansson BG; Hagmar B; Johansson B; Rylander E; Dillner J
    J Natl Cancer Inst; 2009 Jan; 101(2):88-99. PubMed ID: 19141778
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HPV testing compared with routine cytology in cervical screening: long-term follow-up of ARTISTIC RCT.
    Gilham C; Sargent A; Kitchener HC; Peto J
    Health Technol Assess; 2019 Jun; 23(28):1-44. PubMed ID: 31219027
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of HPV-positive women in cervical screening using results from two consecutive screening rounds.
    Polman NJ; Veldhuijzen NJ; Heideman DAM; Snijders PJF; Meijer CJLM; Berkhof J
    Int J Cancer; 2019 May; 144(9):2339-2346. PubMed ID: 30565673
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of human papillomavirus testing for the detection of invasive cervical cancers and cervical intraepithelial neoplasia: a randomised controlled trial.
    Ronco G; Giorgi-Rossi P; Carozzi F; Confortini M; Dalla Palma P; Del Mistro A; Ghiringhello B; Girlando S; Gillio-Tos A; De Marco L; Naldoni C; Pierotti P; Rizzolo R; Schincaglia P; Zorzi M; Zappa M; Segnan N; Cuzick J;
    Lancet Oncol; 2010 Mar; 11(3):249-57. PubMed ID: 20089449
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Real-world research on cervical cancer screening program and effect evaluation for Chinese population].
    Zhao YQ; Dai Y; Dang L; Kong LH; Zhang Y; Feng RM; Qiao YL; Lang JH
    Zhonghua Zhong Liu Za Zhi; 2018 Oct; 40(10):764-771. PubMed ID: 30392341
    [No Abstract]   [Full Text] [Related]  

  • 16. A pilot study of HPV DNA and cytology testing in 50,159 women in the routine Mexican Social Security Program.
    Lazcano-Ponce E; Lörincz AT; Salmerón J; Fernández I; Cruz A; Hernández P; Mejia I; Hernández-Avila M
    Cancer Causes Control; 2010 Oct; 21(10):1693-700. PubMed ID: 20617376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. HPV DNA testing in population-based cervical screening (VUSA-Screen study): results and implications.
    Rijkaart DC; Berkhof J; van Kemenade FJ; Coupe VM; Rozendaal L; Heideman DA; Verheijen RH; Bulk S; Verweij W; Snijders PJ; Meijer CJ
    Br J Cancer; 2012 Feb; 106(5):975-81. PubMed ID: 22251922
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Protocol for Compass: a randomised controlled trial of primary HPV testing versus cytology screening for cervical cancer in HPV-unvaccinated and vaccinated women aged 25-69 years living in Australia.
    Canfell K; Saville M; Caruana M; Gebski V; Darlington-Brown J; Brotherton J; Heley S; Castle PE
    BMJ Open; 2018 Jan; 8(1):e016700. PubMed ID: 29374658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human papillomavirus test with cytology triage in organized screening for cervical cancer.
    Veijalainen O; Kares S; Kujala P; Tirkkonen M; Vuento R; Kholová I; Luukkaala T; Osuala V; Mäenpää J
    Acta Obstet Gynecol Scand; 2016 Nov; 95(11):1220-1227. PubMed ID: 27591407
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of variations in triage cytology interpretation on human papillomavirus-based cervical screening and implications for screening algorithms.
    Ronco G; Zappa M; Franceschi S; Tunesi S; Caprioglio A; Confortini M; Del Mistro A; Carozzi F; Segnan N; Zorzi M; Giorgi-Rossi P;
    Eur J Cancer; 2016 Nov; 68():148-155. PubMed ID: 27755998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.